Evidence map›Paper›PMID 31153803›Full record

ArticleBioorganic & medicinal chemistry letters2019

Development of bivalent compounds as potential neuroprotectants for Alzheimer's disease.

Liu He, Yuqi Jiang, Jakob Green, Hallie Blevins, Shijun Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioorganic & medicinal chemistry letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Liu HeDepartment of Medicinal Chemistry, Virginia Commonwealth University, Richmond, VA, USA.
Yuqi JiangDepartment of Medicinal Chemistry, Virginia Commonwealth University, Richmond, VA, USA.
Jakob GreenDepartment of Medicinal Chemistry, Virginia Commonwealth University, Richmond, VA, USA.
Hallie BlevinsDepartment of Medicinal Chemistry, Virginia Commonwealth University, Richmond, VA, USA.
Shijun ZhangDepartment of Medicinal Chemistry, Virginia Commonwealth University, Richmond, VA, USA. Electronic address: szhang2@vcu.edu.

Funding

Research Supplement to Promote Diversity in Health Related ResearchUL1TR002649 · NCATS · VIRGINIA COMMONWEALTH UNIVERSITY · PI MOELLER, FREDERICK GERARD · 2018 to 2022
$19.1M
Development of NLRP3 inflammasome inhibitors towards Alzheimer's diseaseR01AG058673 · NIA · VIRGINIA COMMONWEALTH UNIVERSITY · PI WANG, XIANG-YANG SHAWN, ZHANG, SHIJUN · 2018 to 2020
$2.3M
Novel bivalent multifunctional ligands towards Alzheimer's diseaseR01AG041161 · NIA · VIRGINIA COMMONWEALTH UNIVERSITY · PI ZHANG, SHIJUN · 2012 to 2016
$1.5M
NCATS NIH HHS UL1 TR002649NIA NIH HHS R01 AG041161NIA NIH HHS R01 AG058673
6 · The paper itself

Abstract

In our efforts to further investigate the impact of the spacer and membrane anchor to the neuroprotective activities, a series of bivalent compounds that contain cholesterol and extended spacers were designed, synthesized and biologically characterized. Our results support previous studies that incorporation of a piperazine ring into the spacer significantly improved the protective potency of bivalent compounds in MC65 cell model. Spacer length beyond 21 atoms does not add further benefits with 21MO being the most potent one with an EC

Indexed as

Alzheimer DiseaseDrug DesignHumansNeuroprotective AgentsNeuroprotective AgentsAlzheimer’s diseaseBivalent compoundsMedicinal chemistryRational drug designSAR

Identifiers

PMID31153803
PMCPMC6938236

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.